GGrantIndex
Sort

21,453 grants matching tuberculosis

IeDEA Asia-Pacific Research Collaboration

$2,522,324
Annette H Sohn · Foundation For Aids Research · U01 · FY2025 · AI

Emory- Duke- Orlando- CDC (EmDOC) Clinical Trials Unit

$2,518,885
Jeffrey Lennox · Emory University · UM1 · FY2014 · AI

BUILDING GLOBAL CAPACITY FOR DIAGNOSTIC TESTING OF TUBERCULOSIS, MALARIA AND HIV

$2,515,037
Heidi Albert · Foundation/Innovative New Diagnostics · U2G · FY2011 · PS

TUBERCULOSIS ELIMINATION AND LABORATORY

$2,514,031
Michelle Conner · Georgia State Dept Of Human Resources · U52 · FY2008 · PS

Excess cardiovascular inflammation in TB and HIV: EXFIN-TB

$2,513,201
Gregory P. Bisson · University Of Pennsylvania · R01 · FY2025 · HL

Metabolic factors that control the spectrum of human tuberculosis

$2,504,101
David Branch Moody · Brigham And Women'S Hospital · U19 · FY2021 · AI

Integrated system for Category C infectious disease diagnostics in resource-limi

$2,500,809
Darrell P Chandler · Harvard Medical School · U19 · FY2015 · AI

AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections

$2,500,001
Judith S. Currier · University Of California Los Angeles · UM1 · FY2023 · AI

International Epidemiologic Databases to Evaluate AIDS - Southern Africa (IeDEA-SA)

$2,500,000
Matthias Egger · Universitat Bern · U01 · FY2016 · AI

COLLABORATIVE AIDS PROGRAMME OF RESEARCH IN SOUTH AFRICA

$2,500,000
Salim S Abdool Karim · University Of Kwazulu-Natal · U19 · FY2006 · AI

Novel weapon evolution in mycobacterial pathogenesis, dispersal and ecological persistence

$2,499,999
Mark E Benbow · Michigan State University · · FY2019 · BIO

Adjuvant Development in the context of a vaccine to protect against tuberculosis

$2,494,333
Vaxine Pty Ltd · N01 · FY2018 · AI

Pathway Analysis in Tuberculosis

$2,492,917
Sabine Ehrt · Weill Medical Coll Of Cornell Univ · P01 · FY2021 · AI

Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplication

$2,492,623
Ian Matthias Sanne · Wits Health Consortium (Pty), Ltd · UM1 · FY2023 · AI

Development of Vaccines to Prevent Tuberculosis

$2,490,549
Robert A Seder · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI

Translational Approaches for Pathogens of Human Significance

$2,490,273
Jennifer F Friedman · Rhode Island Hospital · P20 · FY2025 · GM

HPMI: Host Pathogen Mapping Initiative

$2,489,172
Nevan J Krogan · University Of California, San Francisco · U19 · FY2023 · AI

Caribbean, Central and South America network for HIV epidemiology (CCASnet)

$2,488,424
Catherine C McGowan · Vanderbilt University · U01 · FY2013 · AI

Vanderbilt HIV Clinical Trials Unit

$2,487,433
David W Haas · Vanderbilt University Medical Center · UM1 · FY2020 · AI

Pathway Analysis in Tuberculosis

$2,480,141
Sabine Ehrt · Weill Medical Coll Of Cornell Univ · P01 · FY2022 · AI

Discovery of natural product-based drugs from bacterial symbionts of insects

$2,479,629
Cameron Robert Currie · University Of Wisconsin-Madison · RC4 · FY2010 · GM

Rapid Tests for Drug Resistance to Detect Extensively Drug-Resistant Tuberculosis

$2,478,524
Antonino None Catanzaro · University Of California, San Diego · U01 · FY2009 · AI

CENTERS FOR DISEASE CONTROL AND PREVENTION, TUBERCULOSIS ELIMINATION, LABORATORY

$2,476,791
L Masae Kawamura · San Francisco Department Of Public Health · U52 · FY2011 · PS

HPMI: Host Pathogen Mapping Initiative

$2,475,950
Nevan J Krogan · University Of California, San Francisco · U19 · FY2024 · AI

Development of Therapeutic Candidates for Biodefense, Antimicrobial Resistant (AMR) Infections and Emerging Infectious Diseases

$2,475,623
Nader Fotouhi · Global Alliance For Tb Drug Development · N01 · FY2024 · AI